Evan Weber, PhD, and a research team from CHOP and Stanford Medicine discovered that the protein FOXO1 plays a key role in regulating CAR T cells’ longevity and effectiveness.
In this Q&A, Drs. Teachey and Diorio discuss their partnership and research of a novel CAR T-cell therapy for one of the most common pediatric cancers.
Cookies for Kids’ Cancer, a nonprofit foundation dedicated to pediatric cancer research, uses the proceeds from its cookie sales and other fundraising events to provide grants to support the work of scientists at five of the nation’s leading pediatric cancer centers.
An innovative cell therapy for this stubborn form of leukemia continues to show highly promising results in children treated in a pilot clinical trial.
Dr. Grupp has received a great deal of attention for his investigation of using cell therapy to treat an aggressive form of childhood leukemia, acute lymphoblastic leukemia (ALL).
The investigators, Stephen A. Grupp, MD, PhD and Carl H. June, MD, engineered T cells - the workhorses of the immune system, which recognized and attack invading disease cells - to selectively kill another type of immune cell called B cells, which had become cancerous.
According to new research from The Children's Hospital of Philadelphia and the University of Pennsylvania,
